MedTrace Logo

LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)

NCT06584552 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-06-03

No results posted yet for this study

Summary

The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.

Conditions

Interventions

DIETARY_SUPPLEMENT

Lactobacillus Paracasei LPB27

Probiotic

OTHER

Maltodextrin

Placebo

Sponsors & Collaborators

  • Evolution Health Pty Ltd

    collaborator UNKNOWN

  • The University of New South Wales

    lead OTHER

Principal Investigators

  • Keith CY Ooi · University of New South Wales

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
3 Months
Max Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-15
Primary Completion
2026-03-31
Completion
2026-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06584552 on ClinicalTrials.gov